Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis.
Cerebrovascular diseases (Basel, Switzerland) · 2022-12-29 · Meta-analysis
Abstract
INTRODUCTION: Tirofiban has been used as a rescue when thrombectomy is not successful in endovascular therapy (EVT) for acute ischemic stroke (AIS), but the use of tirofiban after intravenous thrombolysis (IVT) is controversial. The purpose of this meta-analysis was to evaluate the safety and efficacy of tirofiban combined with IVT in AIS compared with not receiving tirofiban. METHODS: The PubMed and Embase databases were searched for all relevant studies published up to August 31, 2021. The safety endpoints included symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and mortality. The efficacy endpoint was the modified Rankin Scale (mRS) score at the 3-month follow-up. RESULTS: Seven articles (1,036 patients) were included. Of these, 444 patients received tirofiban, and 592 patients did not. Meta-analysis showed that tirofiban did not increase the risk of sICH (OR 0.98; 95% CI 0.50-1.93; p = 0.96), any ICH (OR 0.94; 95% CI 0.63-1.39; p = 0.75) or mortality (OR 0.67; 95% CI 0.39-1.15; p = 0.15) and tended to be associated with a favorable functional outcome (OR 1.33; 95% CI 0.99-1.78; p = 0.06) in patients with AIS. Subgroup analysis showed that bridging therapy combined with tirofiban could reduce mortality (OR 0.47; 95% CI 0.23-0.98; p = 0.04). Tirofiban significantly improved the favorable functional outcome in patients with IVT only (non-EVT) (OR 1.98; 95% CI 1.30-3.02; p = 0.002). CONCLUSION: Intravenous tirofiban could be safe for patients with AIS undergoing IVT, regardless of receiving EVT. Intravenous tirofiban may reduce mortality rates for patients undergoing bridging therapy. It also could increase the likelihood of a favorable functional outcome, especially for patients receiving IVT only.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antithrombotics & thrombolytics · Thrombolytics · Mortality & survival · Quality of life & function · GP IIb/IIIa inhibitors
Related articles
- Efficacy and safety of adjuvant tirofiban versus intravenous thrombolysis alone in acute ischemic stroke: an updated meta-analysis of randomized controlled trials. (J Thromb Thrombolysis, 2026)
- Efficacy and safety of tirofiban combined with intravenous thrombolysis in Acute ischemic stroke: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials and observational studies. (Neurol Res, 2026)
- Adjunct tirofiban after intravenous thrombolysis in acute ischemic stroke: a GRADE-guided meta-analysis of randomized trials with trial sequential analysis. (J Thromb Thrombolysis, 2026)
- Safety of Current Therapies for Cardiogenic Cerebral Embolism: A Systematic Review (JEVTM, 2025)
- Intravenous Thrombolysis Plus Tirofiban in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. (J Emerg Med, 2025)
- Efficacy and safety of tirofiban plus recombinant tissue plasminogen activator versus recombinant tissue plasminogen activator alone in acute ischemic stroke patients: a meta-analysis. (J Stroke Cerebrovasc Dis, 2025)